Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Receivables - Other (2016 - 2025)

Historic Receivables - Other for Syndax Pharmaceuticals (SNDX) over the last 11 years, with Q3 2025 value amounting to $3.7 million.

  • Syndax Pharmaceuticals' Receivables - Other rose 571.43% to $3.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.7 million, marking a year-over-year increase of 571.43%. This contributed to the annual value of $3.6 million for FY2024, which is 19625.1% up from last year.
  • According to the latest figures from Q3 2025, Syndax Pharmaceuticals' Receivables - Other is $3.7 million, which was up 571.43% from $3.6 million recorded in Q2 2025.
  • Syndax Pharmaceuticals' Receivables - Other's 5-year high stood at $13.1 million during Q2 2022, with a 5-year trough of $158000.0 in Q1 2022.
  • In the last 5 years, Syndax Pharmaceuticals' Receivables - Other had a median value of $3.4 million in 2023 and averaged $2.7 million.
  • As far as peak fluctuations go, Syndax Pharmaceuticals' Receivables - Other skyrocketed by 292586.61% in 2022, and later plummeted by 9592.43% in 2023.
  • Over the past 5 years, Syndax Pharmaceuticals' Receivables - Other (Quarter) stood at $429000.0 in 2021, then surged by 709.79% to $3.5 million in 2022, then tumbled by 64.68% to $1.2 million in 2023, then soared by 196.25% to $3.6 million in 2024, then increased by 1.79% to $3.7 million in 2025.
  • Its Receivables - Other was $3.7 million in Q3 2025, compared to $3.6 million in Q2 2025 and $3.6 million in Q1 2025.